Propanc Biopharma Announces Publication of Pilot Study Demonstrating Potent Anti-Tumor Efficacy of PRP Pancreatic Proenzyme Formulation in Pancreatic & Ovarian Cancer
Propanc Biopharma announced publication of a peer-reviewed pilot study in Scientific Reports showing potent anti-tumor efficacy of its PRP pancreatic proenzyme formulation across 24 human cancer cell lines. In orthotopic mouse models, daily IV PRP cut mean pancreatic tumor weight by 85.9% and ovarian tumor weight by ~50%, with no treatment-related adverse events.
Key figures
- Drug Name
- PRP (Trypsinogen and Chymotrypsinogen A 1:6 proenzyme formulation)
- Phase Of Trial
- Preclinical / retrospective clinical cohort
- Uk cohort patients
- 46
- Cancer cell lines tested
- 24
- Fibrous capsule reduction
- 57%
- Uk cohort mean survival months
- 9
- Uk cohort expected survival months
- 5.6
- Tumor weight reduction ovarian model
- ~50%
- Uk cohort survival beyond expectancy
- 19 patients (41.3%)
- Tumor weight reduction pancreatic model
- 85.9%
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.